Skip to main content

Table 1 JIS-prevalence of the metabolic syndrome and of its components by using both high and low WC cut-off values (102/88 and 94/80) respectively among adults aged 18-69 years in the ORISCAV-LUX study

From: Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study

 

n

JIS-94/80*

(n = 1320)

JIS-102/88†

(n = 1319)

Abdominal obesity

102/88 cut-off

(n = 1348)

Abdominal obesity

94/80 cut-off

(n = 1348)

Raised TG

(n = 1320)

Low HDL-C

(n = 1320)

High BP

(n = 1348)

Hyperglycaemia

(n = 1317)

Total

1349

28.0

(25.9 - 30.2)

24.7

(22.7 - 26.8)

30.6

(28.4 - 33.0)

51.7

(49.2 - 54.1)

25.6

(23.5 - 27.9)

18.8

(16.8 - 20.9)

52.5

(50.1 - 54.8)

21.7

(19.7 - 23.7)

Gender

         

Women

692

20.4

(17.9 - 23.2)

18.5

(16.1 - 21.2)

35.1

(31.8 - 38.4)

57.7

(54.2 - 61.2)

14.7

(12.4 - 17.4)

16.2

(13.7 - 19.1)

42.2

(39.1 - 45.4)

14.4

(12.1 - 16.7)

Men

657

35.5

(32.2 - 38.9)

30.8

(27.6 - 34.0)

26.3

(23.3 - 29.6)

45.7

(42.2 - 49.2)

36.5

(33.0 - 40.2)

21.3

(18.5 - 24.6)

62.5

(59.0 - 65.9)

29

(25.8 - 32.2)

P-value

 

< 0.0001

< 0.0001

0.0002

< 0.0001

< 0.0001

0.014

< 0.0001

< 0.0001

Age (years)

         

Women

         

18-29

108

1.90

(0.5 - 7.4)

0.90

(0.1 - 6.4)

11.2

(6.5 - 18.6)

30.1

(22.6 - 38.9)

4.2

(1.6 - 10.2)

6.9

(3.3 - 14.0)

11.1

(6.3 - 18.7)

0.00 (-)

30-39

165

9.6

(5.8 - 15.5)

7.8

(4.5 - 13.1)

30.2

(23.6 - 37.8)

56.1

(48.0 - 63.8)

8.8

(5.3 - 14.4)

9.5

(5.7 - 15.5)

27.0

(20.4 - 34.7)

5.2

(2.7 - 9.9)

40-49

175

18.6

(13.4 - 25.2)

16.3

(11.4 - 22.6)

34.5

(27.6 - 42.1)

58.0

(50.4 - 65.2)

10.0

(6.2 - 15.7)

13.8

(9.2 - 20.2)

42.6

(35.6 - 49.8)

18.3

(13.2 - 24.9)

50-59

140

37.8

(30.2 - 46.2)

34.2

(26.8 - 42.4)

48.2

(40.3 - 56.2)

71.3

(63.4 - 78.1)

20.2

(14.3 - 27.7)

20.3

(14.3 - 28.1)

66.7

(58.6 - 73.9)

31.0

(24.0 - 39.0)

60-69

104

50.8

(41.0 - 60.6)

49.8

(40.0 - 59.7)

66.7

(57.4 - 75.8)

88.0

(80.2 - 92.9)

42.6

(32.2 - 52.6)

41.8

(32.5 - 51.7)

89.0

(80.6 - 94.0)

27.5

(19.8 - 36.7)

P-value

 

< 0.0001

< .0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

Men

         

18-29

98

9.5

(5.1 - 17.1)

7.5

(3.6 - 15.0)

8.1

(4.1 - 15.4)

15.9

(10.2 - 23.9)

15.1

(9.1 - 24.2)

10.9

(5.8 - 19.6)

36.0

(27.5 - 45.6)

9.5

(5.0 - 17.4)

30-39

156

18.2

(12.9 - 25.1)

17.1

(12.0 - 23.9)

18.0

(12.8 - 24.7)

36.4

(29.3 - 44.1)

29.6

(22.9 - 37.3)

11.8

(7.6 - 17.9)

50.9

(43.2 - 58.6)

16.4

(11.3 - 23.2)

40-49

180

43.1

(35.9 - 50.5)

34.4

(27.6 - 41.8)

32.9

(26.4 - 40.1)

54.0

(46.6 - 61.2)

42.1

(34.9 - 49.7)

21.2

(15.8 - 27.7)

67.2

(60.1 - 73.7)

33.7

(27.2 - 41.0)

50-59

129

57.5

(48.6 - 66.0)

52.1

(43.2 - 60.8)

40.1

(31.9 - 49.0)

65.1

(56.2 - 73.0)

50.1

(41.5 - 58.7)

31.2

(23.9 - 39.7)

83.7

(76.1 - 89.2)

45.4

(36.9 - 54.1)

60-69

94

68.3

(57.8 - 77.3)

60.4

(50.0 - 70.0)

43.1

(33.9 - 52.7)

73.6

(63.2 - 81.9)

56.7

(46.4 - 66.5)

43.7

(33.7 - 54.2)

93.1

(85.5 - 96.8)

54.5

(44.0 - 64.6)

P-value

 

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< .0001

  1. *JIS-MS based on WC ≥ 94 cm (men) and ≥ 80 cm (women) thresholds. † JIS-MS based on WC ≥ 102 cm (men) and ≥ 88 cm (women) thresholds, i.e. exactly consistent with the R-ATPIII criteria. Data are expressed as percentages (CI 95%). Non-fasting subjects were eliminated from the analysis.